Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07232602 | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) | recruiting | Phase 1 / Phase 2 | 55 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 1, 2026 | clinicaltrials |
| NCT07294664 | PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | recruiting | Phase 2 | 78 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 |
| Sep 1, 2026 |
| clinicaltrials |
| NCT07371234 | Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Rui YouOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07428993 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | recruiting | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07486817 | Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab | recruiting | Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer(OC) | recruiting | Phase 1 / Phase 2 | 72 | Tubulis GmbHINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07797816 | Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer | recruiting | Phase 2 | 31 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05272826 | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients(BOREALIS) | recruiting | Phase 2 | 75 | Canadian Myeloma Research GroupOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05726292 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | recruiting | Phase 2 | 90 | University of ChicagoOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | recruiting | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06086704 | Study of 18F-FFNP Breast PET/MRI | recruiting | Phase 2 | 53 | University of Wisconsin, MadisonOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06108232 | Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | recruiting | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06138275 | Elranatamab in R/R Multiple Myeloma | recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06460298 | ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 51 | ProDa BioTech, LLCINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06600698 | Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA | recruiting | Phase 1 / Phase 2 | 45 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06654336 | Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)(RATIONAL) | recruiting | Phase 2 | 162 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07070440 | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | recruiting | Phase 1 / Phase 2 | 180 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07077161 | Cabozantinib Dose Skipping as an Alternative to Dose Reductions(SKIPPY 2) | recruiting | Phase 2 | 34 | dr. Tom van der HulleOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07079475 | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | recruiting | Phase 1 / Phase 2 | 220 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | recruiting | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07310784 | A Phase II Trial of LM103 in Advanced Melanoma | recruiting | Phase 2 | 92 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07322341 | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07408128 | Partner4Exercise Study(P4E RCT) | recruiting | Phase 2 / Phase 3 | 183 | McMaster UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07460986 | A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.(BEXAR) | recruiting | Phase 1 / Phase 2 | 278 | MedSIROTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 62 | Natalie CallanderOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07551583 | Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL | recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07631650 | Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients | recruiting | Phase 2 | 40 | Matthew SpectorOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07714668 | A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | recruiting | Phase 2 | 171 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07734038 | Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | recruiting | Phase 2 | 155 | Kerry RogersOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796113 | Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | recruiting | Phase 2 | 24 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04677816 | Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients | recruiting | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05344833 | Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma(HEME-18) | recruiting | Phase 2 | 50 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05588141 | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06528496 | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06529718 | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients(SEVILLA) | recruiting | Phase 2 | 72 | UNICANCEROTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT06596694 | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | recruiting | Phase 1 / Phase 2 | 180 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Aug 28, 2026 | clinicaltrials |
| NCT06648889 | Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 28 | Goethe UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06683755 | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06687772 | CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant(CNS-PHLAT) | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | recruiting | Phase 2 | 27 | University of WashingtonOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06854250 | Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer | recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06952868 | Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers | recruiting | Phase 2 | 24 | China Medical University HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07057791 | Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer(PrE0510) | recruiting | Phase 2 | 60 | PrECOG, LLC.OTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07070466 | Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Sep 1, 2026source: clinicaltrials